Tuesday 23 April 2024
Internal Reference Number: FOI_6299
Date Request Received: 17/09/2021 00:00:00
Date Request Replied To: 11/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Dermatology department and Psoriasis treatments
Request Category: Researcher
| Question Number 1: Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: Adalimumab - Humira 5 Adalimumab - Biosimilar 19 Apremilast 2 Bimekizumab 0 Brodalumab 7 Certolizumab 3 Dimethyl Fumarate 0 Etanercept - Enbrel 0 Etanercept - Biosimilar 0 Guselkumab 9 Infliximab - Remicade 0 Infliximab - Biosimilar 0 Ixekizumab 4 Risankizumab 0 Secukinumab 5 Tildrakizumab 1 Ustekinumab 17 | |
| Question Number 2: How many patients have been treated for Psoriasis ONLY in the last three months with the following: • Ciclosporin • Methotrexate - any form and strength • Methotrexate injections 15mg and above | |
| Answer To Question 2: Unable to answer as we do not have access to information on indication for ciclosporin or methotrexate | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
